For example, studies could consider a triple therapy design, simultaneously targeting glucose metabolism (LDHA inhibitor), lipid metabolism (FASN inhibitor), and immune checkpoints (anti-PD-1), and remodeling the “hot tumor” microenvironment through metabolic reprogramming. Here, FASN is linked to neoplasm.